Back to Research

Organization profile

Rheon Medical

Rheon Medical is a high-growth Swiss medtech company that developed the eyeWatch, the world’s first non-invasively adjustable glaucoma drainage system. An EPFL spin-off, the firm utilizes advanced micromechanical and magnetic control technology to allow ophthalmologists to precisely titrate intraocular pressure in an office-based procedure, significantly improving surgical safety and long-term vision preservation.

Préverenges, SwitzerlandFounded 2010

Overview

1. Executive Summary (Confidence: High)

Rheon Medical represents a "Revolution in Glaucoma Treatment," addressing the single greatest clinical challenge in ophthalmic surgery: the lack of post-operative flow control.[23] Founded as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL), the company has commercialized the eyeWatch, a device that integrates Swiss watchmaking precision with advanced medical micromechanics.[23] Since receiving the CE Mark in 2019 and FDA Breakthrough Device Designation in 2021, Rheon has successfully implanted the system in over 1,250 patients worldwide.[23] Clinical data across one- and three-year periods demonstrate an exceptional ability to maintain target intraocular pressure () while reducing the need for medications by up to 60%.[27] Positioned as the primary innovator in the refractory glaucoma market, Rheon is currently scaling its global distribution and pursuing full US regulatory approval.[26]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.